bcl-2抑制剂治疗伴t(11;14)浆细胞病的研究进展  

Progress of bcl-2 inhibitors in treatment of plasma cell disorders with t(11;14)

作　　者：于海搏 黄仲夏[1] Yu Haibo;Huang Zhongxia(Department of Hematology and Oncology,Beijing Chao-yang Hospital,Capital Medical University,Beijing 100043,China)

机构地区：[1]首都医科大学附属北京朝阳医院西院血液与肿瘤科,北京100043

出　　处：《白血病．淋巴瘤》2022年第6期377-380,共4页Journal of Leukemia & Lymphoma

基　　金：北京市科技计划(Z171100000417010);北京市石景山区医学重点专科建设项目。

摘　　要：浆细胞病是一组起源于浆细胞的异质性疾病,包括多发性骨髓瘤、浆细胞白血病和轻链型淀粉样变等,可在骨髓、受累组织中检测到单克隆浆细胞,血清或尿液中检测到单克隆免疫球蛋白及成分,并有一些终末器官受损。伴有t(11;14)的浆细胞病具有独特的生物学特征,对蛋白酶体抑制剂的反应不理想。随着t(11;14)易位,cyclin D1和抗凋亡蛋白bcl-2的表达相对较高,导致浆细胞疾病的发生,影响疾病预后。维奈克拉是一种bcl-2抑制剂,其单药或联合其他药物治疗伴t(11;14)浆细胞病取得了良好效果。文章就bcl-2抑制剂治疗伴t(11;14)浆细胞病的研究进展进行综述。Plasma cell disorders are a group of heterogeneous diseases originating from plasma cells,including multiple myeloma,plasma cell leukemia and light-chain amyloidosis,etc.Monoclonal plasma cells are detected in bone marrow and affected tissues,monoclonal immunoglobulin or components are detected in serum or urine,and some end-organs are injured.Plasma cell disorders accompanied by t(11;14)have unique biological characteristics and unsatisfactory response to proteasome inhibitors.With t(11;14)translocation,the expressions of cyclin D1 and anti-apoptotic protein bcl-2 are relatively high,which lead to the occurrence of plasma cell disorders and have implications for the prognosis of disease.Venetoclax is a bcl-2 inhibitor,and its single agent or combined with other drugs has achieved good efficacy in treatment of plasma cell disorders with t(11;14).This article reviews the progress of bcl-2 inhibitors in treatment of plasma cell disorders.

关 键 词：多发性骨髓瘤 白血病 浆细胞 轻链 淀粉样变性 基因 BCL-2 

分 类 号：R733[医药卫生—肿瘤] R552[医药卫生—临床医学]